| Stereochemistry | ACHIRAL |
| Molecular Formula | C16H13F2NO4S |
| Molecular Weight | 353.341 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(=O)(=O)NC1=C(OC2=C(F)C=C(F)C=C2)C=C3C(=O)CCC3=C1
InChI
InChIKey=CXJONBHNIJFARE-UHFFFAOYSA-N
InChI=1S/C16H13F2NO4S/c1-24(21,22)19-13-6-9-2-4-14(20)11(9)8-16(13)23-15-5-3-10(17)7-12(15)18/h3,5-8,19H,2,4H2,1H3
| Molecular Formula | C16H13F2NO4S |
| Molecular Weight | 353.341 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Flosulide, a selective cyclooxygenase-2 (COX-2) inhibitor, was studied for the treatment for inflammatory diseases. It was shown, that selective inhibition of COX-2 could alter renal function and could be useful in the therapy of esophageal cancer. Experiments on rodent have revealed that therapeutic use of flosulide in proteinuria could be a benefit.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 21.0 nM [IC50] |
